World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
75
Citations
59405
World Ranking
1946
National Ranking
50

Overview

Mark E. Dudley is affiliated with Novartis in Switzerland and has contributed extensively to the fields of medicine, immunology, and oncology. Their research encompasses molecular biology, pathology, genetics, and several specialized areas within immunology and microbiology.

The scientist's research focuses mainly on CAR-T cell therapy and cancer immunotherapy, with key interests in immune cell function and interaction, biosimilars, bioanalytical methods, immunotherapy and immune responses, lymphoma diagnosis and treatment, and virus-based gene therapy. These topics reflect an emphasis on the mechanisms of immune cell activity and cancer treatment modalities.

Mark E. Dudley has published in a variety of venues, most frequently in:

  • Regular and Young Investigator Award Abstracts
  • Frontiers in Immunology
  • Nature Reviews Drug Discovery

Their recent papers include:

  • "Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes," 2023, Frontiers in Immunology
  • "379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor," 2020, Regular and Young Investigator Award Abstracts
  • "373 Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion," 2021, Regular and Young Investigator Award Abstracts
  • "426 Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) drives distinct cytokine-mediated proliferation responses in CD4+ and CD8+ T cells," 2023, Regular and Young Investigator Award Abstracts
  • "95 Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro," 2020, Regular and Young Investigator Award Abstracts

Frequent co-authors collaborating with Mark E. Dudley include:

  • Martina Sýkorová
  • Robert E. Hawkins
  • Gray Kueberuwa
  • John S. Bridgeman
  • Gareth J. Betts

Best Publications

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

    Richard A Morgan;James C Yang;Mio Kitano;Mark E Dudley

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Adoptive cell transfer: a clinical path to effective cancer immunotherapy

    Steven A. Rosenberg;Nicholas P. Restifo;James C. Yang;Richard A. Morgan

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  • Adoptive immunotherapy for cancer: harnessing the T cell response

    Nicholas P. Restifo;Mark E. Dudley;Steven A. Rosenberg

  • Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

    James N. Kochenderfer;Mark E. Dudley;Sadik H. Kassim;Robert P.T. Somerville

  • Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

    Mojgan Ahmadzadeh;Laura A. Johnson;Bianca Heemskerk;John R. Wunderlich

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

    James N. Kochenderfer;Mark E. Dudley;Steven A. Feldman;Wyndham H. Wilson

  • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

    Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  • Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

    Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  • Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

    James N. Kochenderfer;Wyndham H. Wilson;John E. Janik;Mark E. Dudley

  • Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

    Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

    Alena Gros;Paul F. Robbins;Xin Yao;Yong F. Li

  • Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients

    Mark E. Dudley;John R. Wunderlich;Thomas E. Shelton;Jos Even

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
John R. Wunderlich
John R. Wunderlich National Institutes of Health
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Paul F. Robbins
Paul F. Robbins National Cancer Institute
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health
James N. Kochenderfer
James N. Kochenderfer National Institutes of Health
Daniel J. Powell
Daniel J. Powell University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing advanced degrees in nursing and healthcare can open doors to impactful careers. Many professionals transition into specialized roles like Psychiatric-Mental Health Nurse Practitioner (PMHNP), where understanding immune system interactions is increasingly valuable.

Exploring the what is the easiest np program can help prospective students find manageable paths to becoming nurse practitioners. This is particularly helpful for busy individuals balancing education and work.

Additionally, choosing from the best pmhnp programs ensures strong clinical experiences, which are critical for success in healthcare settings. For budget-conscious learners, the cheapest online pmhnp programs provide accessible education without compromising quality.

Understanding career outcomes is essential. Evaluating the dnp salary by state can help candidates make informed decisions about where to study and practice, aligning education choices with long-term financial goals.

Best Scientists Citing Mark E. Dudley

Trending Scientists